This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levy, D. G. Articles by Funder, J. W. Search for Related Content PubMed PubMed Citation Articles by Levy, D. G. Articles by Funder, J. W.

Distinguishing the Antihypertensive and Electrolyte Effects of Eplerenone

Pfizer Inc. (D.G.L., R.R.), Peapack, New Jersey 07977; and Prince Henry’s Institute of Medical Research (J.W.F.), Clayton 3168, Victoria, Australia

Address all correspondence and requests for reprints to: Prof. J. W. Funder, Prince Henry’s Institute of Medical Research, P.O. Box 5152, Clayton 3168, Victoria, Australia. E-mail: John.Funder{at}phimr.monash.edu.au.

In two clinical trials on the antihypertensive effects of the mineralocorticoid receptor antagonist eplerenone 397 essential hypertensives were dose titrated (50, 100, and 200 mg/d) over successive 4-wk periods until they reached target blood pressure levels. Of the total, 44% reached target on 50 mg/d, 17% on 100 mg/d, and 19% on 200 mg/d, with 20% failing to do so despite stepwise dose increases. At each dose level, those who reached target (responders) were compared with those who did not (nonresponders), with three major findings. First, at each dose level, the blood pressure fall in responders (systolic, 16–20 mm Hg; diastolic, 15 mm Hg) was markedly more than mean values in nonresponders (systolic, 2–5 mm Hg; diastolic, 1–3 mm Hg). Second, sensitivity to eplerenone varied widely across the population studied in terms of blood pressure reduction. Third, there was no difference in plasma [K⁺] levels between responders and nonresponders at any dose level. We interpret these data as evidence for the major antihypertensive effect of eplerenone being via mechanisms other than those involving epithelial electrolyte and fluid transport. The modest (0.2 mEq/liter at 200 mg/d) mean elevation in plasma [K⁺] suggests that titration to effect rather than forced titration may minimize the risk of hyperkalemia, even where relatively high (100–200 mg/d) doses of the specific mineralocorticoid receptor antagonist eplerenone may ultimately be required.

This work was presented at the annual meetings of the American Society of Hypertension (May 2003) and the European Society for Hypertension (June 2003).

Present address for R.R.: Novartis Corporation, New Hanover, New Jersey 01770.

Present address for D.G.L.: Hoffman-La Roche Inc., Nutley, New Jersey 07936.

Abbreviations: BP, Blood pressure; DBP, diastolic BP; SBP, systolic BP.

This article has been cited by other articles:

				J. W. Funder Aldosterone and the Cardiovascular System: Genomic and Nongenomic Effects Endocrinology, December 1, 2006; 147(12): 5564 - 5567. [Abstract] [Full Text] [PDF]

				J. Lepenies and M. Quinkler MR blockade in patients with chronic renal disease--not the more the merrier, but the earlier the better Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3343 - 3344. [Full Text] [PDF]

				M. Quinkler, D. Zehnder, K. S. Eardley, J. Lepenies, A. J. Howie, S. V. Hughes, P. Cockwell, M. Hewison, and P. M. Stewart Increased Expression of Mineralocorticoid Effector Mechanisms in Kidney Biopsies of Patients With Heavy Proteinuria Circulation, September 6, 2005; 112(10): 1435 - 1443. [Abstract] [Full Text] [PDF]

				J. W. Funder Aldosterone, Normotension, and Diastolic Dysfunction J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5500 - 5501. [Full Text] [PDF]

				J. W. Funder Aldosterone-Renin Ratios in the Context of Primary Care J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4219 - 4220. [Full Text] [PDF]